Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Single-Cell Transcriptome Analyses Reveal Endothelial Cell Heterogeneity in Tumors and Changes following Antiangiogenic Treatment

Qi Zhao, Alexandra Eichten, Asma Parveen, Christina Adler, Ying Huang, Wei Wang, Yueming Ding, Alexander Adler, Thomas Nevins, Min Ni, Yi Wei, Gavin Thurston

Cancer Res (2018) 78 (9): 2370–2382.

https://doi.org/10.1158/0008-5472.CAN-17-2728

Published: 30 April 2018

View articletitled, Single-Cell Transcriptome Analyses Reveal Endothelial Cell Heterogeneity in Tumors and Changes following Antiangiogenic Treatment

Includes: Supplementary data

Journal Articles

Resistance to Anti-VEGF Therapy Mediated by Autocrine IL6/STAT3 Signaling and Overcome by IL6 Blockade

Alexandra Eichten, Jia Su, Alexander P. Adler, Li Zhang, Ella Ioffe, Asma A. Parveen, George D. Yancopoulos, John Rudge, Israel Lowy, Hsin Chieh Lin, Douglas MacDonald, Christopher Daly, Xunbao Duan, Gavin Thurston

Cancer Res (2016) 76 (8): 2327–2339.

https://doi.org/10.1158/0008-5472.CAN-15-1443

Published: 14 April 2016

View articletitled, Resistance to Anti-VEGF Therapy Mediated by Autocrine IL6/STAT3 Signaling and Overcome by IL6 Blockade

Includes: Supplementary data

Journal Articles

Abstract 1378: Evasive resistance to VEGF blockade mediated by autocrine IL-6/STAT3 signaling in xenograft models of human cancer

Alexander P. Adler, Alexandra Eichten, Li Zhang, Jia Su, Ella Ioffe, George D. Yancopoulus, Douglas MacDonald, Christopher Daly, Xunbao Duan, Gavin Thurston

Cancer Res (2015) 75 (15_Supplement): 1378.

https://doi.org/10.1158/1538-7445.AM2015-1378

Published: 01 August 2015

View articletitled, Abstract 1378: Evasive resistance to VEGF blockade mediated by autocrine IL-6/STAT3 signaling in xenograft models of human cancer

Journal Articles

Abstract 4492: Blockade of angiopoietin-2 or Tie2 is equally effective at inhibiting tumor growth and reducing tumor vessel density in most human tumor xenograft models

Alexander P. Adler, Christopher Daly, Asma A. Parveen, Thomas Nevins, Jing Shan, Jeanette Fairhurst, Tammy Huang, Joel Martin, Nicholas Papadopoulos, George D. Yancopoulos, Gavin Thurston, Gavin Thurston, Alexandra Eichten

Cancer Res (2014) 74 (19_Supplement): 4492.

https://doi.org/10.1158/1538-7445.AM2014-4492

Published: 01 October 2014

View articletitled, Abstract 4492: Blockade of angiopoietin-2 or Tie2 is equally effective at inhibiting tumor growth and reducing tumor vessel density in most human tumor xenograft models

Journal Articles

Abstract 5092: Ziv-aflibercept treatment reduces intra-hepatic tumor growth of a preclinical colorectal carcinoma liver metastasis model, monitored using non-invasive micro-ultrasound and bioluminescent imaging.

Alexander P. Adler, Asma Parveen, Gavin Thurston, Alexandra Eichten

Cancer Res (2013) 73 (8_Supplement): 5092.

https://doi.org/10.1158/1538-7445.AM2013-5092

Published: 15 April 2013

View articletitled, Abstract 5092: Ziv-aflibercept treatment reduces intra-hepatic tumor growth of a preclinical colorectal carcinoma liver metastasis model, monitored using non-invasive micro-ultrasound and bioluminescent imaging.

Journal Articles

Angiopoietin-2 Functions as a Tie2 Agonist in Tumor Models, Where It Limits the Effects of VEGF Inhibition

Christopher Daly, Alexandra Eichten, Carla Castanaro, Elizabeth Pasnikowski, Alexander Adler, Alshad S. Lalani, Nicholas Papadopoulos, Alastair H. Kyle, Andrew I. Minchinton, George D. Yancopoulos, Gavin Thurston

Cancer Res (2013) 73 (1): 108–118.

https://doi.org/10.1158/0008-5472.CAN-12-2064

Published: 02 January 2013

View articletitled, Angiopoietin-2 Functions as a Tie2 Agonist in Tumor Models, Where It Limits the Effects of VEGF Inhibition

Includes: Supplementary data

Journal Articles

Abstract 2723: Sarilumab (REGN88), a fully-human anti-IL6R antibody, inhibits tumor growth in preclinical models, as a single agent and in combination with the VEGF blocker aflibercept

Li Zhang, Bo Luan, Alexander Adler, Alexandra Eichten, Christopher Daly, Gavin Thurston

Cancer Res (2012) 72 (8_Supplement): 2723.

https://doi.org/10.1158/1538-7445.AM2012-2723

Published: 15 April 2012

View articletitled, Abstract 2723: Sarilumab (REGN88), a fully-human anti-IL6R antibody, inhibits tumor growth in preclinical models, as a single agent and in combination with the VEGF blocker aflibercept

Journal Articles

Abstract 3290: REGN910, a fully-human, Ang2-specific monoclonal antibody, inhibits tumor growth as a monotherapy and dramatically potentiates the effects of VEGF Trap (aflibercept)

Christopher Daly, Carla Castanaro, Alexander P. Adler, Alexandra Eichten, Alshad S. Lalani, Nicholas J. Papadopoulos, Gavin Thurston

Cancer Res (2011) 71 (8_Supplement): 3290.

https://doi.org/10.1158/1538-7445.AM2011-3290

Published: 15 April 2011

View articletitled, Abstract 3290: REGN910, a fully-human, Ang2-specific monoclonal antibody, inhibits tumor growth as a monotherapy and dramatically potentiates the effects of VEGF Trap (aflibercept)

Journal Articles

Abstract 4246: Enhanced anti-vascular and anti-tumor effects upon combination therapy with aflibercept (VEGF Trap) and other anti-angiogenic drugs

Alexander P. Adler, Pranitha Vangala, Carla Castanaro, Christopher Daly, Gavin Thurston, Alexandra Eichten

Cancer Res (2011) 71 (8_Supplement): 4246.

https://doi.org/10.1158/1538-7445.AM2011-4246

Published: 15 April 2011

View articletitled, Abstract 4246: Enhanced anti-vascular and anti-tumor effects upon combination therapy with aflibercept (VEGF Trap) and other anti-angiogenic drugs

Journal Articles

Abstract 390: Correlation of the effects of antiangiogenic agents aflibercept (VEGF Trap) and anti-Dll4 antibody on tumor vascular perfusion and tumor growth

Alexander P. Adler, Alexandra Eichten, Asma A. Parveen, Gavin Thurston

Cancer Res (2010) 70 (8_Supplement): 390.

https://doi.org/10.1158/1538-7445.AM10-390

Published: 15 April 2010

View articletitled, Abstract 390: Correlation of the effects of antiangiogenic agents aflibercept (VEGF Trap) and anti-Dll4 antibody on tumor vascular perfusion and tumor growth

Journal Articles

Identifying tumor vascular genes regulated by Aflibercept (VEGF Trap)

Alexander Adler, Alexandra Eichten, Chiayi Kao, Yi Wei, Wen Fury, Calvin Lin, Gavin Thurston

Cancer Res (2008) 68 (9_Supplement): 2497.

Published: 01 May 2008

View articletitled, Identifying tumor vascular genes regulated by Aflibercept (VEGF Trap)

Journal Articles

Distinctive Features of Angiogenesis and Lymphangiogenesis Determine Their Functionality during De novo Tumor Development

Alexandra Eichten, William C. Hyun, Lisa M. Coussens

Cancer Res (2007) 67 (11): 5211–5220.

https://doi.org/10.1158/0008-5472.CAN-06-4676

Published: 01 June 2007

View articletitled, Distinctive Features of Angiogenesis and Lymphangiogenesis Determine Their Functionality during De novo Tumor Development

Journal Articles

Unique response pathways are engaged by blood and lymphatic endothelial cells during cancer development

Alexandra Eichten, Lisa M. Coussens

Cancer Res (2006) 66 (8_Supplement): 248.

Published: 15 April 2006

View articletitled, Unique response pathways are engaged by blood and lymphatic endothelial cells during cancer development

Journal Articles

Microenvironmental regulation of lymphatic metastasis development

Alexandra Eichten, Lisa M. Coussens

Cancer Res (2004) 64 (7_Supplement): 335.

Published: 01 April 2004

View articletitled, Microenvironmental regulation of lymphatic metastasis development

Update search

NARROW

Format

Subjects

Journal

Article Type

Issue Section

Date

Availability

Single-Cell Transcriptome Analyses Reveal Endothelial Cell Heterogeneity in Tumors and Changes following Antiangiogenic Treatment

Resistance to Anti-VEGF Therapy Mediated by Autocrine IL6/STAT3 Signaling and Overcome by IL6 Blockade

Abstract 1378: Evasive resistance to VEGF blockade mediated by autocrine IL-6/STAT3 signaling in xenograft models of human cancer

Abstract 4492: Blockade of angiopoietin-2 or Tie2 is equally effective at inhibiting tumor growth and reducing tumor vessel density in most human tumor xenograft models

Abstract 5092: Ziv-aflibercept treatment reduces intra-hepatic tumor growth of a preclinical colorectal carcinoma liver metastasis model, monitored using non-invasive micro-ultrasound and bioluminescent imaging.

Angiopoietin-2 Functions as a Tie2 Agonist in Tumor Models, Where It Limits the Effects of VEGF Inhibition

Abstract 2723: Sarilumab (REGN88), a fully-human anti-IL6R antibody, inhibits tumor growth in preclinical models, as a single agent and in combination with the VEGF blocker aflibercept

Abstract 3290: REGN910, a fully-human, Ang2-specific monoclonal antibody, inhibits tumor growth as a monotherapy and dramatically potentiates the effects of VEGF Trap (aflibercept)

Abstract 4246: Enhanced anti-vascular and anti-tumor effects upon combination therapy with aflibercept (VEGF Trap) and other anti-angiogenic drugs

Abstract 390: Correlation of the effects of antiangiogenic agents aflibercept (VEGF Trap) and anti-Dll4 antibody on tumor vascular perfusion and tumor growth

Identifying tumor vascular genes regulated by Aflibercept (VEGF Trap)

Distinctive Features of Angiogenesis and Lymphangiogenesis Determine Their Functionality during De novo Tumor Development

Unique response pathways are engaged by blood and lymphatic endothelial cells during cancer development

Microenvironmental regulation of lymphatic metastasis development

Email alerts

AACR Journals

Update search

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only